News
HOUSTON, TX / ACCESS Newswire / July 9, 2025 / Mann Eye Institute, a leader in innovative eye care since the 1970s, is proud ...
This is a developing news story. Please check back soon for updates. Alcon will acquire LumiThera, including its ...
Sean Clark, the VP and general manager of Alcon’s Global Surgical Franchise, added: “Dry AMD is an area of significant unmet ...
Alcon has inked a deal to acquire LumiThera and its light-based therapy for dry age-related macular degeneration, which obtained a groundbreaking FDA clearance late last year. | LumiThera's approach ...
LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...
Monday announced its intention to acquire LumiThera and its PBM device for the treatment of early and intermediate dry AMD.
Alcon to Acquire LumiThera and its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) ...
LumiThera’s Valeda became the first non-invasive approach for treating dry AMD following its authorisation by the US Food and Drug Administration (FDA) in November 2024.
LumiThera, Inc. is an ophthalmic medical device company that is Harnessing the Power of Light ™ to offer a comprehensive approach for detecting, treating, and monitoring retinal diseases ...
LumiThera wants patients to have access to non-invasive Valeda treatments to improve vision and address the disease earlier in the process,” stated Clark Tedford, Ph.D., LumiThera President and CEO.
LumiThera is a commercial-stage medical device company focused on treating people affected by ocular damage and disease including dry Age-related Macular Degeneration, a leading cause of blindness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results